Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 201–300 of 1,001
Applications of RNA Interference in Mammalian Systems
Martin, S. E., & Caplen, N. J. (2007) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.8.080706.092424 · Cited by 158
Singh, N. P., Singh, U. P., Rouse, M., Zhang, J., Chatterjee, S., Nagarkatti, P. S., & Nagarkatti, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501727 · Cited by 133
Alarcón-Arís, D., Recasens, A., Galofré, M., Carballo-Carbajal, I., Zacchi, N., Ruiz-Bronchal, E., Pavia-Collado, R., Chica, R., Ferrés-Coy, A., Santos, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.015 · Cited by 134
Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets?
Grimm, D., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300116 · Cited by 137
“16 Although the detailed mechanism of toxicity is still under investigation, in line with our in vivo data, other groups have consistently reported concentration-dependent cytotoxic effects from shRNA overexpression in cultured cells.”
BackgroundResultInfluentialSelf-citationViral vector-mediated RNA interference
Couto, L. B., & High, K. A. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.007 · Cited by 139
“In the HBV transgenic mouse model, decreasing the dose of an AAV vector expressing a 19mer anti-HBV shRNA from 1 10(12) vg/mouse to 3 10(11) vg/mouse resulted in sustained (>4 mo) reduction in HBV surface antigen, and a 2–3 log decrease in serum viral DNA, in the absence of toxicity, indicating that this simple soluti…”
BackgroundMethodInfluentialBarth, B. M., Sharma, R., Altınoğlu, E. İ., Morgan, T. T., Shanmugavelandy, S. S., Kaiser, J. M., McGovern, C. O., Matters, G. L., Smith, J. P., KESTER, M. A., et al. (2010) · ACS Nano · doi:10.1021/nn901297q · Cited by 136
“have been under investigation; however, hepatotoxicity and immunogenicity have been reported.(34) The use of”
Bron, R., Vermeren, M., Kokot, N., Andrews, W. D., Little, G. E., Mitchell, K. J., & Cohen, J. (2007) · Neural Development · doi:10.1186/1749-8104-2-21 · Cited by 135
“Second, off-target and non-specific effects have been widely reported [43-45] and are a serious concern when using RNAi.”
BackgroundKoutsaki, M., Spandidos, D. A., & Zaravinos, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.022 · Cited by 136
RNA viruses and the host microRNA machinery
tenOever, B. R. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2971 · Cited by 141
Vigilance and Validation: Keys to Success in RNAi Screening
Sigoillot, F. D., & King, R. W. (2011) · ACS Chemical Biology · doi:10.1021/cb100358f · Cited by 127
de Rougemont, O., Lehmann, K., & Clavien, P. (2009) · Liver Transplantation · doi:10.1002/lt.21876 · Cited by 146
“In mice, the overload of the physiological micro-RNA pathway by RNAi was a lethal condition.(89) The use of RNAi in humans is further limited by several factors.”
BackgroundOligonucleotide therapeutic approaches for Huntington disease
Sah, D. W. Y., & Aronin, N. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45130 · Cited by 132
“A compelling example is overexpression of AAV-shRNA in mouse liver, which led to hepatocyte death (100).”
BackgroundApplications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Lundberg, C., Bjorklund, T., Carlsson, T., Jakobsson, J., Hantraye, P., Deglon, N., & Kirik, D. (2008) · Current Gene Therapy · doi:10.2174/156652308786847996 · Cited by 134
“Similar results were obtained in the liver where U6 promoter appeared to have higher efficiency however, U6 driven shRNA expression was shown to cause saturation of the micro RNA pathway leading to toxicity in liver cells in vivo [104].”
ResultKhetarpal, S. A., Schjoldager, K. T., Christoffersen, C., Raghavan, A., Edmondson, A. C., Reutter, H. M., Ahmed, B., Ouazzani, R., Peloso, G. M., Vitali, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.012 · Cited by 129
“Subsequent studies by others have shown that high doses of AAV shRNA expression in the liver can mediate hepatotoxicity due to oversaturation of microRNA (miRNA) export pathways from the nucleus and reduction of essential miRNAs (Grimm et al., 2006).”
BackgroundCurrent and Possible Future Therapeutic Options for Huntington’s Disease
Ferguson, M. W., Kennedy, C. J., Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221092517 · Cited by 147
C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection
Barmania, F., & Pepper, M. S. (2013) · Applied & Translational Genomics · doi:10.1016/j.atg.2013.05.004 · Cited by 160
“The disadvantages of expressing siRNAs range from off target mRNA degradation (Jackson et al., 2006) to cytotoxicity (Grimm et al., 2006).”
BackgroundHuang, S., Duan, S., Wang, J., Bao, S., Qiu, X., Li, C., Liu, Y., Yan, L., Zhang, Z., & Hu, Y. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201504912 · Cited by 131
Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications
Huang, C., Li, M., Chen, C., & Yao, Q. C. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.5.637 · Cited by 141
“There are several other options available such as shRNA expression from inducible or tissue-specific RNA polymerase II promoters to overcome this competition between siRNA/shRNA and miRNA pathways [53] .”
BackgroundMiniarikova, J., Zanella, I., Huseinovic, A., van der Zon, T., Hanemaaijer, E., Martier, R., Koornneef, A., Southwell, A. L., Hayden, M. R., van Deventer, S. J., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.7 · Cited by 132
Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry
Wang, P., Zhou, Y., & Richards, M. (2021) · Theranostics · doi:10.7150/thno.62642 · Cited by 140
“As this procedure requires nuclear transcription processing with the potential risk of over-saturating the miRNA biogenesis pathway, shRNA dose and sequence must be carefully optimized [64].”
BackgroundShort Hairpin RNA-Mediated Gene Silencing
Lambeth, L. S., & Smith, C. A. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-119-6_12 · Cited by 152
Sætrom, P., Snøve, O., & Rossi, J. J. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e318045760e · Cited by 143
Carmona, S., Jorgensen, M. R., Kolli, S., Crowther, C. E., Salazar, F. H., Marion, P. L., Fujino, M., Natori, Y., Thanou, M., Arbuthnot, P. B., et al. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800157x · Cited by 127
Self-citationIntracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don’t
Juliano, R. L. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0727 · Cited by 123
miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction
Guda, S., Brendel, C., Renella, R., Du, P., Bauer, D. E., Canver, M. C., Grenier, J. K., Grimson, A. W., Kamran, S. C., Thornton, J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.113 · Cited by 123
Maintaining the silence: reflections on long-term RNAi
Raemdonck, K., Vandenbroucke, R. E., Demeester, J., Sanders, N. N., & Smedt, S. C. D. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.008 · Cited by 133
“153 Grimm, D. and Kay, M.A. (2007) Combinatorial RNAi: a winning strategy for the”
BackgroundInfluentialWallace, L. M., Liu, J., Domire, J. S., Garwick-Coppens, S. E., Guckes, S., Mendell, J. R., Flanigan, K. M., & Harper, S. Q. (2012) · Molecular Therapy · doi:10.1016/s1525-0016(16)35977-9 · Cited by 134
Novel RNA-based Strategies for Therapeutic Gene Silencing
Sibley, C. R., Seow, Y., & Wood, M. J. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.306 · Cited by 134
Carbonell, A., de Alba, Á. E. M., Flores, R., & Gago‐Zachert, S. (2007) · Virology · doi:10.1016/j.virol.2007.09.031 · Cited by 121
“Interestingly , over-saturation of cellular microRNA/short hairpin RNA pathways has also been associated with fatality in mice (Grimm et al., 2006).”
BackgroundChang, C. I., Yoo, J. W., Hong, S. W., Lee, S. E., Kang, H. S., Sun, X., Rogoff, H. A., Ban, C., Kim, S., Li, C. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.298 · Cited by 118
Psatha, N., Reik, A., Phelps, S., Zhou, Y., Dalas, D., Yannaki, E., Levasseur, D. N., Urnov, F. D., Holmes, M. C., & Papayannopoulou, T. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.003 · Cited by 115
Jones, R. D., Qian, Y., Siciliano, V., DiAndreth, B., Huh, J., Weiss, R., & Del Vecchio, D. (2020) · Nature Communications · doi:10.1038/s41467-020-19126-9 · Cited by 115
Khodr, C. E., Sapru, M. K., Pedapati, J., Han, Y., West, N. C., Kells, A. P., Bankiewicz, K. S., & Bohn, M. C. (2011) · Brain Research · doi:10.1016/j.brainres.2011.04.036 · Cited by 116
“…effects are thought to result from saturation of endogenous RNAi machinery by high shRNA levels, leading to interference of miRNA processing (Boudreau et al., 2008; Boudreau et al., 2009; Castanotto et al., 2007; Diederichs et al., 2008; Grimm et al., 2006; McBride et al., 2008; Yi et al., 2005).”
BackgroundTherapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1 G93A Mice and Nonhuman Primates
Borel, F., Gernoux, G., Cardozo, B., Metterville, J. P., T. Cabrera, G., Song, L., Su, Q., Gao, G. P., Elmallah, M. K., Brown, R. H., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.122 · Cited by 110
“43,44 49 Although in the NHP robust silencing was observed only with the U6-driven construct, optimization of the expression cassette and delivery technique may improve knockdown with the CB-driven construct.”
MethodMueller, C., Tang, Q., Gruntman, A., Blomenkamp, K., Teckman, J., Song, L., Zamore, P. D., & Flotte, T. R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.292 · Cited by 117
“12 Similarly other early reports noted striatal neurotoxicity in mice treated with shRNA targeting the huntingtin gene and Purkinje cell loss in mice treated with shRNA against SCA1 .”
BackgroundIn Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma
Martínez, T., González, M. V., Roehl, I., Wright, N., Pañeda, C., & Jiménez, A. I. (2014) · Molecular Therapy · doi:10.1038/mt.2013.216 · Cited by 113
siRNA delivery using peptide transduction domains
Eguchi, A., & Dowdy, S. F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.009 · Cited by 115
MicroRNAs as targets for antisense-based therapeutics
Stenvang, J., & Kauppinen, S. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.1.59 · Cited by 116
“The importance of functional miRNA processing is highlighted by high fatality in mice, when the processing pathway is inhibited by oversaturation with short-hairpin RNA (shRNA) [62] .”
BackgroundAagaard, L. A., Zhang, J., von Eije, K. J., Li, H., Sætrom, P., Amarzguioui, M., & Rossi, J. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.147 · Cited by 115
Competition for RISC binding predicts in vitro potency of siRNA
Koller, E., Propp, S. S., Murray, H., Lima, W. F., Bhat, B., Prakash, T. P., Allerson, C. R., Swayze, E. E., Marcusson, E. G., & Dean, N. M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl589 · Cited by 125
“(23) published the interesting finding that mice treated with high doses of viral vectors carrying genes encoding shRNAs can suffer from hepatotoxicity.”
Blazev, R., Carl, C. S., Ng, Y.-K., Molendijk, J., Voldstedlund, C. T., Zhao, Y., Xiao, D., Kueh, A. J., Miotto, P. M., Haynes, V. R., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.003 · Cited by 112
Fine‐tuning of the innate immune response by microRNAs
Gantier, M. P., Sadler, A. J., & Williams, B. R. G. (2007) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100091 · Cited by 126
Xu, W., Jiang, X., & Huang, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64046-8.00282-2 · Cited by 124
Off-targeting and other non-specific effects of RNAi experiments in mammalian cells.
Svoboda, P. (2007) · PubMed · Cited by 125
Breast cancer and microRNAs: therapeutic impact
Iorio, M. V., Casalini, P., Piovan, C., Braccioli, L., & Tagliabue, E. (2011) · The Breast · doi:10.1016/s0960-9776(11)70297-1 · Cited by 121
Takahashi, Y., Nishikawa, M., & Takakura, Y. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.006 · Cited by 110
Efficient in vivo microRNA targeting of liver metastasis
Huynh, C., Segura, M., Gaziel-Sovran, A., Menéndez, S., Darvishian, F., Chiriboga, L., Levin, B., Meruelo, D., Osman, I., Zavadil, J., et al. (2011) · Oncogene · doi:10.1038/onc.2010.523 · Cited by 114
“Our data show that anti-miR therapy administered by intraperitoneal injection according to the mentioned schedules is generally safe, as opposed to the fatal liver toxicity observed with small hairpin RNA therapy (Grimm et al., 2006).”
BackgroundBennasser, Y., Chable-Bessia, C., Triboulet, R., Gibbings, D., Gwizdek, C., Dargemont, C., Kremer, E. J., Voinnet, O., & Benkirane, M. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1987 · Cited by 109
“Because intracellular expression levels of XPO5 are limiting, it can be saturated by overexpression of its substrates in vivo”
BackgroundMartin, J. N., Wolken, N., Brown, T., Dauer, W. T., Ehrlich, M. E., & Gonzalez-Alegre, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.10 · Cited by 108
Non-coding RNAs: a key to future personalized molecular therapy?
Galasso, M., Elena Sana, M., & Volinia, S. (2010) · Genome Medicine · doi:10.1186/gm133 · Cited by 108
“Nevertheless, a study [ 67 ] has also shown that such an approach can cause fatality in mice, possibly resulting from oversaturation of the cellular miRNA/short hairpin RNA pathway (shRNA; a short sequence of RNA that makes a tight hairpin turn and can be used to silence gene expression).”
BackgroundThe Role of MicroRNAs in Diabetic Nephropathy
Wu, H., Kong, L., Zhou, S., Cui, W., Xu, F., Luo, M., Li, X., Tan, Y., & Miao, L. (2014) · Journal of Diabetes Research · doi:10.1155/2014/920134 · Cited by 113
“The knockdown effect of shRNAs on the expression of target gene was striking and stable [74]; however, it might saturate the Exportin 5 pathway of endogenous miRNAs, leading to off-target effects with fatal consequences [97].”
BackgroundTargeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
Evers, M. M., Pepers, B. A., van Deutekom, J. C. T., Mulders, S. A. M., den Dunnen, J. T., Aartsma-Rus, A., van Ommen, G.-J. B., & van Roon-Mom, W. M. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024308 · Cited by 103
“strand, [58] as well as striatal toxicity [32,59].”
BackgroundMicroRNAs as therapeutic targets in human cancers
Shah, M., & Călin, G. A. (2014) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1229 · Cited by 122
Valastyan, S., Chang, A., Benaich, N., Reinhardt, F., & Weinberg, R. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0410 · Cited by 107
RetractedmiRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy
Sabir, N., Hussain, T. A., Shah, S. Z. A., Peramo, A., Zhao, D., & Zhou, X. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00602 · Cited by 118
“…the activity of downregulated antimycobacterial miRNAs by using synthetic oligos and reduce the effects of overexpressed pro-mycobacterial miRNAs through antisense oligonucleotides or anti-miRNA complementary to mature miRNA (Meister et al., 2004; Grimm et al., 2006; Baumann and Winkler, 2014).”
BackgroundProlonged gene silencing by combining siRNA nanogels and photochemical internalization
Raemdonck, K., Naeye, B., Høgset, A., Demeester, J., & Smedt, S. C. D. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.012 · Cited by 106
“On the other hand, major concerns are raised with regard to adverse effects of siRNA therapeutics, such as unwanted immune activation [17], off-target silencing [18] and saturation of the RNAi machinery [19].”
BackgroundThe Regulatory Activities of Plant MicroRNAs: A More Dynamic Perspective
Meng, Y., Shao, C., Wang, H., & Chen, M. (2011) · PLANT PHYSIOLOGY · doi:10.1104/pp.111.187088 · Cited by 119
“Vol. 157, 2011 1585 In animals, manually introduced short hairpin RNAs could interfere with the expression of endogenous miRNA genes through drastic competition for the nuclear exportation and processing machineries (Grimm et al., 2006; Stewart et al., 2008).”
BackgroundEmerging Role of miRNAs in the Drug Resistance of Gastric Cancer
Riquelme, I., Letelier, P. J., Riffo‐Campos, Á. L., Brebi, P., & Roa, J. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030424 · Cited by 107
“Although the toxicity-inducing mechanism is not well known, this toxicity might be caused by two main reasons: (1) a dose-dependent oversaturation of siRNAs or shRNAs within cells [83], likely because these molecules have a lower propensity to be processed by Pol-II compared to miRNA-based treatments [81]; (2) a disru…”
BackgroundCurrent Strategies for Inhibition of Chikungunya Infection
Subudhi, B. B., Chattopadhyay, S., Mishra, P., & Kumar, A. (2018) · Viruses · doi:10.3390/v10050235 · Cited by 111
“However, intracellular degradation still remains a hurdle in its application [153].”
BackgroundGe, Q., Brichard, S., Yi, X., & Li, Q. (2014) · Journal of Immunology Research · doi:10.1155/2014/987285 · Cited by 102
RNAi: a potential new class of therapeutic for human genetic disease
Seyhan, A. A. (2011) · Human Genetics · doi:10.1007/s00439-011-0995-8 · Cited by 112
Christiaens, O., Sweet, J. B., Dzhambazova, T., Urru, I., Smagghe, G. J., Kostov, K. V., & Arpaia, S. (2021) · Journal of Pest Science · doi:10.1007/s10340-021-01439-3 · Cited by 108
The biogenesis and characterization of mammalian microRNAs of mirtron origin
Sibley, C. R., Seow, Y., Saayman, S. M., Dijkstra, K. K., Andaloussi, S. E., Weinberg, M. S., & Wood, M. J. A. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr722 · Cited by 129
LIU, Y., YAN, W., ZHANG, W., CHEN, L., YOU, G., BAO, Z., WANG, Y., WANG, H., KANG, C., & JIANG, T. (2012) · Oncology Reports · doi:10.3892/or.2012.1902 · Cited by 102
“Grimm et al reported fatal side effects from abundant RNAi expression in the liver of adult mice (40).”
Therapy development in Huntington disease: From current strategies to emerging opportunities
Dickey, A. S., & Spada, A. R. L. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38494 · Cited by 117
“2004), further studies demonstrated that high-level expression of exogenous shRNAs may cause toxicity (Grimm et al., 2006), prompting the development of artificial miRNA vectors, packaged into AAV, where huntingtin-targeting shRNAs are instead embedded in the”
BackgroundThe Business of RNAi Therapeutics in 2012
Haussecker, D. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2011.9 · Cited by 98
Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging
Li, J., Zhao, M., Su, H., Wang, Y., Tan, C., Ji, L., & Mao, Z. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.011 · Cited by 104
microRNAs and Neurodegenerative Diseases
Qiu, L., Tan, E., & Zeng, L. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22671-2_6 · Cited by 108
Small noncoding RNAs: Biogenesis, function, and emerging significance in toxicology
Choudhuri, S. (2010) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20325 · Cited by 97
“nously supplied siRNA or shRNA was demonstrated both in the cell culture model [101] and in vivo [100].”
BackgroundMlambo, T., Nitsch, S., Hildenbeutel, M., Romito, M., Müller, M., Bossen, C., Diederichs, S., Cornu, T. I., Cathomen, T., & Mussolino, C. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky171 · Cited by 104
Christensen, M. (2010) · Frontiers in Neural Circuits · doi:10.3389/neuro.04.016.2009 · Cited by 99
“…(AACCTTGTGGTCCTTAGGTGCG and cel-miR-67, respectively) which are not natural components of the small RNA pool of rodents, and therefore served as important negative controls for potential non-specifi c effects of small RNA overexpression in general (Grimm et al., 2006; Narvaiza et al., 2006).”
Ribonucleases as Novel Chemotherapeutics: The Ranpirnase Example
Lee, J. E., & Raines, R. T. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00006 · Cited by 106
miRNA cassettes in viral vectors: Problems and solutions
Liu, Y. P., & Berkhout, B. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.05.014 · Cited by 109
“The first study showing that RNAi-related toxicity andmorbidity can occur in mice upon shRNA expression in the liver was performed with AAV8 vectors [58].”
BackgroundCoexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites
Diederichs, S., Jung, S., Rothenberg, S. M., Smolen, G. A., Mlody, B., & Haber, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800803105 · Cited by 113
“Ectopic Ago2 not only optimizes targeted RNAi but also may help minimize nonspecific toxicity attributed to oversaturation of miRNA pathways by high siRNA loads (10): Ago2 coexpression allows a reduction in the concentration of targeting construct required because of its increased potency and provides an additional am…”
BackgroundInfluentialBarrett, C. E., Keebaugh, A. C., Ahern, T. H., Bass, C. E., Terwilliger, E. F., & Young, L. J. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.01.005 · Cited by 100
“RNAi also has limitations in terms of potential off-target effects (Grimm et al., 2006; Manjunath et al., 2009).”
Grimm, D. (2011) · Silence · doi:10.1186/1758-907x-2-8 · Cited by 96
“The aforementioned strategy to deliberately coexpress known rate-limiting cellular RNAi factors can boost shRNA potency and reduce toxicity [2,17], yet the longterm outcomes of this particular approach for the cell and organism remain to be studied.”
BackgroundSelf-citationTherapeutic targeting in the silent era: advances in non-viral siRNA delivery
Guo, J., Fisher, K. A., Darcy, R., Cryan, J. F., & O’Driscoll, C. M. (2010) · Molecular BioSystems · doi:10.1039/c001050m · Cited by 108
Spurgers, K. B., Sharkey, C. M., Warfield, K. L., & Bavari, S. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.12.008 · Cited by 107
Zhou, H., Falkenburger, B. H., Schulz, J. B., Tieu, K., Xu, Z., & Xia, X. G. (2007) · International Journal of Biological Sciences · doi:10.7150/ijbs.3.242 · Cited by 99
“In mammals, expression of shRNA may cause dsRNA-dependent interferon response which is dependent on the sequence length and content of shRNA [29-31].”
BackgroundMethodInfluentialMicroRNAs in Rheumatoid Arthritis: Potential Role in Diagnosis and Therapy
Filková, M., Jüngel, A., Gay, R. E., & Gay, S. (2012) · BioDrugs · doi:10.2165/11631480-000000000-00000 · Cited by 114
“The experiments performed byGrimm et al.([127]) showed that the delivery ofmiRNA/ short hairpin RNAs using an adenoviral vector caused a severe liver injury or even death in mice.”
Applications of Lentiviral Vectors for shRNA Delivery and Transgenesis
Singer, O., & Verma, I. M. (2008) · Current Gene Therapy · doi:10.2174/156652308786848067 · Cited by 99
Pfeffer, S., & Voinnet, O. (2006) · Oncogene · doi:10.1038/sj.onc.1209915 · Cited by 108
“The severe biological consequences of overriding the host miRNA machinery was exemplified recently in adult mice sustaining high level, prolonged short-hairpin (sh)RNA delivery in the liver (Grimm et al., 2006).”
BackgroundDesign of small molecule-responsive microRNAs based on structural requirements for Drosha processing
Beisel, C. L., Chen, Y. Y., Culler, S. J., Hoff, K. G., & Smolke, C. D. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq954 · Cited by 100
Baek, S. T., Kerjan, G., Bielas, S. L., Lee, J. E., Fenstermaker, A. G., Novarino, G., & Gleeson, J. G. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.036 · Cited by 96
“For example, several shRNAs were show to saturate Exportin-5 and cause downregulation of critical miRNAs, causing off-target toxicity (Grimm et al., 2006), but overexpression of Exportin-5 in Dcx shRNA KD cells did not rescue the migration defect (data not shown).”
Ely, A., Naidoo, T., Mufamadi, M. S., Crowther, C. E., & Arbuthnot, P. B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.82 · Cited by 103
Caveat of RNAi in Plants: The Off-Target Effect
Senthil‐Kumar, M., & Mysore, K. S. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-123-9_2 · Cited by 111
“Although silencing might spread to other tissues, the benefit of specific promoters to increase specificity of gene silencing has been demonstrated (2, 39).”
BackgroundNon-coding RNA therapeutics for cardiac regeneration.
Braga, L., Ali, H., Secco, I., & Giacca, M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa071 · Cited by 84
DsRNA-based pesticides: Considerations for efficiency and risk assessment
Dalakouras, A., Koidou, V., & Papadopoulou, K. Κ. (2024) · Chemosphere · doi:10.1016/j.chemosphere.2024.141530 · Cited by 100
MicroRNAs: Key Modulators of Posttranscriptional Gene Expression
O’Hara, S. P., Mott, J. L., Splinter, P. L., Gores, G. J., & LaRusso, N. F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.11.028 · Cited by 101
Defining the optimal parameters for hairpin-based knockdown constructs
Li, L., Li, X., Khvorova, A., Fesik, S. W., & Shen, Y. (2007) · RNA · doi:10.1261/rna.599107 · Cited by 110
“... triggers against the targets of interests are being created, and therapeutic approaches based on vector-expressed silencing triggers are being investigated (Brummelkamp et al. 2002; Miyagishi and Taira 2002; Paddison et al. 2002; Sui et al. 2002; Xia et al. 2002; Brummelkamp et al. 2003; Carmell et al. 2003; Rubin…”
BackgroundEngineered RNA viral synthesis of microRNAs
Varble, A., Chua, M. A., Perez, J. T., Manicassamy, B., García‐Sastre, A., & tenOever, B. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003115107 · Cited by 106
“In contrast, nonintegrating viral vectors have been found to induce ultraphysiological and sustained levels of small RNAs, resulting in toxicity through saturation of the host small RNA cell machinery (24).”
BackgroundCorey, D. R. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0107-8 · Cited by 97
Minicircle DNA vectors for gene therapy: advances and applications
Gaspar, V. M., de Melo‐Diogo, D., Costa, E. C., Moreira, A. F., Queiroz, J. A., Pichon, C., Correia, I. J., & de Sousa, F. P. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.996544 · Cited by 105
“This is a critical parameter, since an over-dose of anti-sense oligonucleotides has shown to induce severe hepatotoxicity following silencing of human a-1 antitrypsin liver enzyme in transgenic mice [6].”
BackgroundBénard, L., Oh, J. G., Cacheux, M., Lee, A., Nonnenmacher, M. E., Matasic, D. S., Kohlbrenner, E., Kho, C., Pavoine, C., Hajjar, R. J., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020678 · Cited by 99
“shLuc was redeveloped by using an antiluciferase sequence that was previously described and validated.(21)”
MethodNext-generation libraries for robust RNA interference-based genome-wide screens
Kampmann, M., Horlbeck, M. A., Chen, Y., Tsai, J. C., Bassik, M. C., Gilbert, L. A., Villalta, J. E., Kwon, S. C., Chang, H., Kim, V. N., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508821112 · Cited by 95
“Although shRNAs can be expressed in mammalian cells from RNA polymerase III promoters, such as the U6 promoter, such strategies can lead to nonspecific toxicity associated with high shRNA expression levels, possibly because of saturation of the endogenous RNAi machinery (10).”
BackgroundMirtrons, an emerging class of atypical miRNA
Curtis, H. J., Sibley, C. R., & Wood, M. J. A. (2012) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1122 · Cited by 102
Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development
Rao, D. D., Senzer, N. N., Cleary, M. A., & Nemunaitis, J. J. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.53 · Cited by 115
MicroRNA epigenetic alterations in human cancer: One step forward in diagnosis and treatment
Yang, N., Coukos, G., & Zhang, L. (2007) · International Journal of Cancer · doi:10.1002/ijc.23325 · Cited by 100
“from AAV vectors in mice could saturate the miRNA pathway and cause severe liver toxicity.(87) Therefore, precautions have to”
BackgroundGuidelines for the optimal design of miRNA-based shRNAs
Ros, X. B., & Gu, S. (2016) · Methods · doi:10.1016/j.ymeth.2016.04.003 · Cited by 104
MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications
van den Berg, N. W. E., Kawasaki, M., Berger, W. R., Neefs, J., Meulendijks, E. R., Tijsen, A. J., & de Groot, J. R. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6736-z · Cited by 98
“AAVs could be used for targeted delivery, but as these rely on the delivery of genetic material, the effects may be permanent and long-term negative effects need to be established [130, 134].”
Background
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.